Finanzen von Larimar Therapeutics Inc (LRMR)LRMRLarimar Therapeutics Inc

Evaluating the bottom line, Larimar Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -139.63%, provide a clear picture of how effectively LRMR converts its operational activities into shareholder value.

In the context of the broader market, LRMR competes directly with industry leaders such as ALEC and ZNTL. With a market capitalization of $253.47M, it holds a significant position in the sector. When comparing efficiency, LRMR's gross margin of N/A stands against ALEC's 100.00% and ZNTL's N/A. Such benchmarking helps identify whether Larimar Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Larimar has reported significant net losses, with Q2 2026 showing a loss of $32.8 million, but it has a strong current ratio of 4.70, indicating good short-term financial health.